MiniMed has appointed Alcon CEO David Endicott and Medtronic executive Linnea Burman to its Board of Directors, expanding the board from nine to 11 members. Endicott brings decades of global healthcare leadership and public company experience, including leading Alcon's spin-out and return to the public markets, and will serve on the Compensation and Talent Committee. Burman, designated by majority shareholder Medtronic following MiniMed's separation and IPO earlier this year, is Senior Vice President and President of Neurovascular at Medtronic and adds MedTech operating depth. The appointments come as MiniMed sharpens execution as an independent diabetes technology company.
MiniMed Group, Inc. Common StockAppointment of experienced leaders strengthens board governance and execution capability as an independent company.
Alcon AG
Medtronic PLC